Scarica l'app Stockscreener
11.62
4.91%
-0.60
Dopo l'orario di chiusura:
11.62
Precedente Chiudi:
$12.22
Aprire:
$12.26
Volume 24 ore:
414.97K
Relative Volume:
0.58
Capitalizzazione di mercato:
$829.79M
Reddito:
$133.62M
Utile/perdita netta:
$-177.37M
Rapporto P/E:
-4.0208
EPS:
-2.89
Flusso di cassa netto:
$23.50M
1 W Prestazione:
+7.39%
1M Prestazione:
-18.00%
6M Prestazione:
+49.94%
1 anno Prestazione:
-28.36%
Intervallo 1D:
$11.25
$12.55
Intervallo di 1 settimana:
$11.01
$12.73
Portata 52W:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
11.62 | 872.64M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-29 | Aggiornamento | Barclays | Underweight → Overweight |
| 2025-09-17 | Ripresa | Barclays | Underweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2024-12-12 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector - Yahoo Finance
EV Market: Does Xencor Inc stock reflect fundamentalsMarket Trend Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet? - 富途牛牛
The Technical Signals Behind (XNCR) That Institutions Follow - Stock Traders Daily
Truist Securities reiterates Buy rating on Xencor stock amid TL1A momentum - Investing.com Nigeria
Xencor (NASDAQ:XNCR) Stock Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Bear Alert: Is Xencor Inc impacted by rising rates2025 Market Outlook & Safe Entry Point Identification - baoquankhu1.vn
Xencor’s Financial Runway Supports Ambitious Clinical Pipeline - AD HOC NEWS
Will Xencor Inc. stock rally after Fed decisionsStock Surge & Daily Stock Trend Watchlist - mfd.ru
Update Report: Can Xencor Inc stock outperform in a bear market2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Xencor, Inc. (XNCR) Stock Analysis: Unlocking a 132.90% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage - Finviz
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Precision Trading with Xencor Inc. (XNCR) Risk Zones - Stock Traders Daily
Contrasting NRx Pharmaceuticals (NASDAQ:NRXP) & Xencor (NASDAQ:XNCR) - Defense World
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - sharewise.com
Xencor, Inc. (XNCR) Stock Analysis: A Biotech Contender With 119.93% Potential Upside - DirectorsTalk Interviews
Activity Recap: Is Xencor Inc impacted by rising ratesQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative? - Yahoo Finance
Market Catalysts: What is the target price for Xencor Inc stockMarket Activity Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
SG Americas Securities LLC Takes Position in Xencor, Inc. $XNCR - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones - Yahoo Finance
Navigating the Valuation Gap in Xencor Shares - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Down 7.1%Here's Why - MarketBeat
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – Time to Sell? - Defense World
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Merger Talk: What hedge fund activity signals for Xencor Inc stockJuly 2025 Action & Accurate Intraday Trade Tips - Bộ Nội Vụ
Performance Recap: Can Xencor Inc stock outperform in a bear marketMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Weekly Earnings: Is Xencor Inc a top pick in the sector2025 Trading Recap & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
ImmunityBio, Xencor Drugs Win E.U. Nods - labusinessjournal.com
Xencor's Clinical Milestone Paves Way for Potential Revaluation () - aktiencheck.de
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Xencor, Inc.Common Stock (NQ: XNCR - FinancialContent
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs By Investing.com - Investing.com Nigeria
IPO Launch: Will Xencor Inc stock reach Wall Street targetsWeekly Trade Summary & Daily Momentum Trading Reports - Bộ Nội Vụ
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail
Will Xencor Inc. stock benefit from upcoming earnings reports2025 Price Targets & Weekly Return Optimization Alerts - Улправда
How Xencor Inc. stock reacts to Fed rate cuts2025 Top Decliners & High Accuracy Investment Entry Signals - Улправда
Will Xencor Inc. stock reach Wall Street targetsQuarterly Investment Review & Community Consensus Trade Alerts - Улправда
Is Xencor Inc. stock in correction or buying zoneQuarterly Profit Summary & AI Based Trade Execution Alerts - ulpravda.ru
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - BioSpace
Xencor expects to have sufficient cash resources to fund research and development programs and operations through 2028 - marketscreener.com
Xencor Expects To Have Sufficient Cash Resources To Fund Research And Development Programs And Operations Through 2028 - TradingView — Track All Markets
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs - Investing.com
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xencor Inc Azioni (XNCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Dec 19 '25 |
Option Exercise |
12.51 |
73,367 |
917,821 |
309,941 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Dec 22 '25 |
Option Exercise |
12.51 |
6,311 |
78,951 |
242,885 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Dec 19 '25 |
Sale |
15.72 |
73,367 |
1,153,329 |
236,574 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 19 '25 |
Option Exercise |
12.51 |
114,377 |
1,430,856 |
581,012 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 22 '25 |
Option Exercise |
12.51 |
10,624 |
132,906 |
477,259 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 19 '25 |
Sale |
15.71 |
114,377 |
1,796,863 |
466,635 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):